ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Aug 2024
Last Updated on 01 Aug 2024
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:

  • Tisagenlecleucel cells dispersion for infusion for treating patients between two to 25 years of age (both ages inclusive) with B-cell acute lymphoblastic leukaemia that is refractory, in relapse post-transplant or in second or later relapse.

Funding status

Tisagenlecleucel cells dispersion for infusion is recommended for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for the abovementioned indication from 1 August 2024.

Tisagenlecleucel should be used in line with the additional clinical criteria listed in the Annex.


Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia (1 Aug 24) PES Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (1 Aug 24)